Nashville

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Amyloidosis3 trials
• Prostate cancer2 trials
• Uveitis2 trials
• Crohn's disease1 trial

Phase

• Phase 36 trials
• Phase 12 trials
• Phase 1/22 trials
• Phase 22 trials

Status

• Completed6 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Alnylam Pharmaceuticals3 trials
• Arvinas Estrogen Receptor, Inc.2 trials
• Olema Pharmaceuticals, Inc.2 trials
• Priovant Therapeutics, Inc.2 trials
• Arvinas Androgen Receptor, Inc.1 trial
• and 2 more

Running trials

• Recruiting

  A Study of SL-325 in Crohn's Disease Patients

  NCT07753850· Phase 2· Shattuck Labs, Inc.· Source

  Contact: Shattuck Medical Director

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

  NCT06431373· Phase 3· Priovant Therapeutics, Inc.· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Crohn's disease1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

  NCT05523765· Phase 2· Priovant Therapeutics, Inc.· Source

• Completed

  ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

  NCT05501769· Phase 1· Arvinas Estrogen Receptor, Inc.· Source

• Completed

  Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

  NCT05177042· Phase 1· Arvinas Androgen Receptor, Inc.· Source

• Completed

  A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

  NCT04072952· Phase 1/2· Arvinas Estrogen Receptor, Inc.· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source

• Completed

  Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT03888612· Phase 1/2· Arvinas Inc.· Source